293 related articles for article (PubMed ID: 22542362)
1. Eculizumab therapy results in rapid and sustained decreases in markers of thrombin generation and inflammation in patients with PNH independent of its effects on hemolysis and microparticle formation.
Weitz IC; Razavi P; Rochanda L; Zwicker J; Furie B; Manly D; Mackman N; Green R; Liebman HA
Thromb Res; 2012 Sep; 130(3):361-8. PubMed ID: 22542362
[TBL] [Abstract][Full Text] [Related]
2. Alterations in markers of coagulation and fibrinolysis in patients with Paroxysmal Nocturnal Hemoglobinuria before and during treatment with eculizumab.
van Bijnen ST; Østerud B; Barteling W; Verbeek-Knobbe K; Willemsen M; van Heerde WL; Muus P
Thromb Res; 2015 Aug; 136(2):274-81. PubMed ID: 26143713
[TBL] [Abstract][Full Text] [Related]
3. Eculizumab effect on the hemostatic state in patients with paroxysmal nocturnal hemoglobinuria.
Seregina EA; Tsvetaeva NV; Nikulina OF; Zapariy AP; Erasov AV; Gribkova IV; Orel EB; Ataullakhanov FI; Balandina AN
Blood Cells Mol Dis; 2015 Feb; 54(2):144-50. PubMed ID: 25497169
[TBL] [Abstract][Full Text] [Related]
4. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria.
Hillmen P; Hall C; Marsh JC; Elebute M; Bombara MP; Petro BE; Cullen MJ; Richards SJ; Rollins SA; Mojcik CF; Rother RP
N Engl J Med; 2004 Feb; 350(6):552-9. PubMed ID: 14762182
[TBL] [Abstract][Full Text] [Related]
5. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria.
Hillmen P; Young NS; Schubert J; Brodsky RA; Socié G; Muus P; Röth A; Szer J; Elebute MO; Nakamura R; Browne P; Risitano AM; Hill A; Schrezenmeier H; Fu CL; Maciejewski J; Rollins SA; Mojcik CF; Rother RP; Luzzatto L
N Engl J Med; 2006 Sep; 355(12):1233-43. PubMed ID: 16990386
[TBL] [Abstract][Full Text] [Related]
6. Extravascular hemolysis and complement consumption in Paroxysmal Nocturnal Hemoglobinuria patients undergoing eculizumab treatment.
Subías Hidalgo M; Martin Merinero H; López A; Anter J; García SP; Ataúlfo Gonzalez-Fernández F; Forés R; Lopez-Trascasa M; Villegas A; Ojeda E; Rodríguez de Córdoba S
Immunobiology; 2017 Feb; 222(2):363-371. PubMed ID: 27644115
[TBL] [Abstract][Full Text] [Related]
7. Perisurgical induction of eculizumab in a patient with paroxysmal nocturnal hemoglobinuria: its inhibition of surgery-triggered hemolysis and the consequence of subsequent discontinuation.
Kurita N; Obara N; Fukuda K; Nishikii H; Sato S; Inagawa S; Kurokawa T; Owada Y; Ninomiya H; Chiba S
Blood Coagul Fibrinolysis; 2013 Sep; 24(6):658-62. PubMed ID: 23917586
[TBL] [Abstract][Full Text] [Related]
8. Treatment of paroxysmal nocturnal hemoglobinuria in the era of eculizumab.
Röth A; Dührsen U
Eur J Haematol; 2011 Dec; 87(6):473-9. PubMed ID: 21883481
[TBL] [Abstract][Full Text] [Related]
9. Different Levels of Incomplete Terminal Pathway Inhibition by Eculizumab and the Clinical Response of PNH Patients.
Harder MJ; Höchsmann B; Dopler A; Anliker M; Weinstock C; Skerra A; Simmet T; Schrezenmeier H; Schmidt CQ
Front Immunol; 2019; 10():1639. PubMed ID: 31379839
[No Abstract] [Full Text] [Related]
10. Neutrophil activation and nucleosomes as markers of systemic inflammation in paroxysmal nocturnal hemoglobinuria: effects of eculizumab.
van Bijnen ST; Wouters D; van Mierlo GJ; Muus P; Zeerleder S
J Thromb Haemost; 2015 Nov; 13(11):2004-11. PubMed ID: 26333021
[TBL] [Abstract][Full Text] [Related]
11. Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and novel anticomplement strategies.
Risitano AM
Adv Exp Med Biol; 2013; 735():155-72. PubMed ID: 23402025
[TBL] [Abstract][Full Text] [Related]
12. Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria.
Hillmen P; Elebute M; Kelly R; Urbano-Ispizua A; Hill A; Rother RP; Khursigara G; Fu CL; Omine M; Browne P; Rosse W
Am J Hematol; 2010 Aug; 85(8):553-9. PubMed ID: 20658586
[TBL] [Abstract][Full Text] [Related]
13. Achievements and limitations of complement inhibition by eculizumab in paroxysmal nocturnal hemoglobinuria: the role of complement component 3.
Risitano AM; Perna F; Selleri C
Mini Rev Med Chem; 2011 Jun; 11(6):528-35. PubMed ID: 21561403
[TBL] [Abstract][Full Text] [Related]
14. Patients with paroxysmal nocturnal hemoglobinuria demonstrate a prothrombotic clotting phenotype which is improved by complement inhibition with eculizumab.
Macrae FL; Peacock-Young B; Bowman P; Baker SR; Quested S; Linton E; Hillmen P; Griffin M; Munir T; Payne D; McKinley C; Clarke D; Newton DJ; Hill A; Ariëns RAS
Am J Hematol; 2020 Aug; 95(8):944-952. PubMed ID: 32311169
[TBL] [Abstract][Full Text] [Related]
15. [Successful management of orthopedic operations requiring general anesthesia in a PNH patient after introduction of eculizumab].
Tsutsui M; Gotoh A; Yasuda H; Ono E; Tanaka M; Komatsu N
Rinsho Ketsueki; 2015 Apr; 56(4):423-7. PubMed ID: 25971274
[TBL] [Abstract][Full Text] [Related]
16. Successful use of eculizumab in a pediatric patient treated for paroxysmal nocturnal hemoglobinuria.
Bauters T; Bordon V; Robays H; Benoit Y; Dhooge C
J Pediatr Hematol Oncol; 2012 Nov; 34(8):e346-8. PubMed ID: 22767128
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of eculizumab in children and adolescents with paroxysmal nocturnal hemoglobinuria.
Reiss UM; Schwartz J; Sakamoto KM; Puthenveetil G; Ogawa M; Bedrosian CL; Ware RE
Pediatr Blood Cancer; 2014 Sep; 61(9):1544-50. PubMed ID: 24777716
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of the terminal complement inhibitor eculizumab in Japanese patients with paroxysmal nocturnal hemoglobinuria: the AEGIS clinical trial.
Kanakura Y; Ohyashiki K; Shichishima T; Okamoto S; Ando K; Ninomiya H; Kawaguchi T; Nakao S; Nakakuma H; Nishimura J; Kinoshita T; Bedrosian CL; Valentine ME; Khursigara G; Ozawa K; Omine M
Int J Hematol; 2011 Jan; 93(1):36-46. PubMed ID: 21222185
[TBL] [Abstract][Full Text] [Related]
19. Phase 3 Study of Subcutaneous Versus Intravenous Ravulizumab in Eculizumab-Experienced Adult Patients with PNH: Primary Analysis and 1-Year Follow-Up.
Yenerel MN; Sicre de Fontbrune F; Piatek C; Sahin F; Füreder W; Ortiz S; Ogawa M; Ozol-Godfrey A; Sierra JR; Szer J
Adv Ther; 2023 Jan; 40(1):211-232. PubMed ID: 36272026
[TBL] [Abstract][Full Text] [Related]
20. Clinical roundtable monograph: Paroxysmal nocturnal hemoglobinuria: a case-based discussion.
Szer J; Hill A; Weitz IC
Clin Adv Hematol Oncol; 2012 Nov; 10(11 Suppl 21):1-16. PubMed ID: 23271156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
